A methylation functional detection hepatic cell system validates correlation between DNA methylation and drug-induced liver injury

Abstract

Drug-induced liver injury (DILI) is a life-threatening, adverse reaction to certain drugs. The onset and extent of DILI can vary drastically in different patients using identical drugs. Association studies suggested that subtle differences in DNA methylation may help explain the individual differences in DILI. However, there are very few experimental methods to confirm such associations. In this study, we established a novel DNA methylation functional detection system in human hepatocytes, using CRISPR/dCas9 for targeted modification of DNA methylation, and set four parameters to indicate the liver injury by cell model. Using this system, we validated the association of hypermethylation of CYP2D6 and CYP2E1 with rifampin-induced DILI. Our results revealed that, following treatment of HepaRG cells with rifampin, the methylation levels of CYP2D6 and CYP2E1 were inversely proportional to cell viability and glutathione content, and directly proportional to caspase 3/7 activity. We expect that our methylation detection system will serve as a useful tool in validating correlations between DNA methylation and DILI in other in vitro systems. Our results establish a foundation for future investigations to better understand the mechanisms underlying DILI and may aid in advancing personalized DILI medicine.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Flow chart of the construction of the functional DNA methylation detection system in human hepatic cells.
Fig. 2
Fig. 3: MS-HRM analysis of modified HepaRG cells.
Fig. 4: Representative data from the mu0ltiparametric assay in which HepaRG-D cells were treated with rifampin.
Fig. 5: Representative data from the multiparametric assay in which HepaRG-M cells were treated with rifampin.

References

  1. 1.

    Fisher K, Vuppalanchi R, Saxena R. Drug-induced liver injury. Arch Pathol Lab Med. 2015;139:876–87.

  2. 2.

    Hunt CM, Papay JI, Stanulovic V, Regev A. Drug rechallenge following drug-induced liver injury. Hepatology. 2017;66:646–54.

  3. 3.

    Amin MD, Harpavat S, Leung DH. Drug-induced liver injury in children. Curr Opin Pediatr. 2015;27:625–33.

  4. 4.

    Chen C. Research advances in drug-induced liver injury and existing problems in China. J Clini Hepatol. 2018;34:1147–51.

  5. 5.

    Wu Y, Geng XC, Wang JF, Miao YF, Lu YL, Li B. The HepaRG cell line, a superior in vitro model to L-02, HepG2 and hiHeps cell lines for assessing drug-induced liver injury. Cell Biol Toxicol. 2016;32:37–59.

  6. 6.

    Katarey D, Verma S. Drug-induced liver injury. Clin Med. 2016;16:s104–9.

  7. 7.

    Choi JM, Oh SJ, Lee JY, Jeon JS, Ryu CS, Kim YM, et al. Prediction of drug-induced liver injury in HepG2 cells cultured with human liver microsomes. Chem Res Toxicol. 2015;28:872–85.

  8. 8.

    Chen R, Zhang Y, Tang S, Lv X, Wu S, Sun F, et al. The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a Case-control Study. J Clin Pharm Ther. 2015;40:110–5.

  9. 9.

    Urban TJ, Daly AK, Aithal GP. Genetic basis of drug-induced liver injury: present and future. Semin Liver Dis. 2014;34:123–33.

  10. 10.

    Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat Rev Genet. 2013;14:204–20.

  11. 11.

    Robertson KD. DNA methylation and human disease. Nat Rev Genet. 2005;6:597–610.

  12. 12.

    Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11:726–34.

  13. 13.

    Meier K, Recillas-Targa F. New insights on the role of DNA methylation from a global view. Front Biosci. 2017;22:644–68.

  14. 14.

    Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology. 2014;146:914–28.

  15. 15.

    Zhang J, Zhu X, Li Y, Zhu L, Li S, Zheng G, et al. Correlation of CpG island methylation of the cytochrome P450 2E1/2D6 genes with liver injury induced by anti-tuberculosis drugs: a nested Case-control Study. Int J Environ Res Public Health. 2016;13:E776.

  16. 16.

    Gunness P, Mueller D, Shevchenko V, Heinzle E, Ingelman-Sundberg M, Noor F. 3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity studies. Toxicol Sci. 2013;133:67–78.

  17. 17.

    Tomida T, Okamura H, Satsukawa M, Yokoi T, Konno Y. Multiparametric assay using HepaRG cells for predicting drug-induced liver injury. Toxicol Lett. 2015;236:16–24.

  18. 18.

    Antherieu S, Chesne C, Li R, Guguen-Guillouzo C, Guillouzo A. Optimization of the HepaRG cell model for drug metabolism and toxicity studies. Toxicol Vitr. 2012;26:1278–85.

  19. 19.

    Aninat C, Piton A, Glaise D, Le Charpentier T, Langouet S, Morel F, et al. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos. 2006;34:75–83.

  20. 20.

    McDonald JI, Celik H, Rois LE, Fishberger G, Fowler T, Rees R, et al. Reprogrammable CRISPR/Cas9-based system for inducing site-specific DNA methylation. Biol Open. 2016;5:866–74.

  21. 21.

    He L, Gao L, Shi Z, Li Y, Zhu L, Li S, et.al. Involvement of Cytochrome P450 1A1 and Glutathione S-Transferase P1 Polymorphisms and Promoter Hypermethylation in the Progression of Anti-Tuberculosis Drug-Induced Liver Injury: A Case–Control Study. PLOS ONE. 2015;10:e0119481.

  22. 22.

    Li Y, Ren Q, Zhu L, Li Y, Li J, Zhang Y, et al. Involvement of methylation of MicroRNA-122, -125b and -106b in regulation of Cyclin G1, CAT-1 and STAT3 target genes in isoniazid-induced liver injury. Bmc Pharmacol Toxicol. 2018;19:11.

  23. 23.

    Li Y, Li Y, Zheng G, Zhu L, Wang J, Mu S, et al. Cytochrome P450 1A1 and 1B1 promoter CpG island methylation regulates rat liver injury induced by isoniazid. Mol Med Rep. 2018;17:753–62.

  24. 24.

    GoMez-LechoN MJ, Tolosa L, Castell JV, Donato MT. Mechanism-based selection of compounds for the development of innovative in vitro approaches to hepatotoxicity studies in the LIINTOP project. Toxicol Vitr. 2010;24:1879–89.

  25. 25.

    Howell LS, Ireland L, Park BK, Goldring CE. MiR-122 and other microRNAs as potential circulating biomarkers of drug-induced liver injury. Expert Rev Mol Diagn. 2018;18:47–54.

Download references

Acknowledgements

This work was supported by grants from the National Nature Science Foundation of China (81773818, 81273596, 30900799, and 81671326), the 863 Program (2012AA02A515, 2012AA021802), National Key Research and Development Program (2016YFC0905000, 2016YFC0905002, 2016YFC1200200, and 2016YFC0906400), the 4th Three-year Action Plan for Public Health of Shanghai (15GWZK0101), Shanghai Pujiang Program (17PJD020), Shanghai Key Laboratory of Psychotic Disorders (13dz2260500), and China Postdoctoral Science Foundation (2017M621450).

Author information

YW and CZ conducted the experiments and drafted the paper. YG, WZ, and MW assisted in experiments and data analysis. CL helped to polish the paper. CH and SQ designed the study. All authors reviewed and approved the paper.

Correspondence to Shengying Qin.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wei, Y., Huai, C., Zhou, C. et al. A methylation functional detection hepatic cell system validates correlation between DNA methylation and drug-induced liver injury. Pharmacogenomics J (2020). https://doi.org/10.1038/s41397-020-0160-7

Download citation